In 2003, gefitinib (Iressa®, AstraZaneca, London, UK) in 250 mg tablet form received accelerated approval by the US Food and Drug Administration. Gefitinib targets the cancer cell at the molecular level and has the ability to palliate lung cancer symptoms. Gefitinib’s ability to control symptoms with minimal toxicity provides physicians with a new option to complement current symptom control methods. It is nonmarrow suppressive and seems to have an ability to control symptoms quickly, even in the absence of obvious tumor reduction. However, further studies are needed to compare gefitinib’s ability to control symptoms with intensive palliative modalities for lung cancer, such as opioids, oxygen, and radiation therapy.
Belani CP, Barstis J, Perry MC, et al.: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003; 21(15): 2933-2939.
2.
Rudd RL: Chemotherapy in the treatment of non-small cell lung cancer. Respir Disease Practice. 1991; 7: 12-15.
3.
Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2): 92-98.
4.
Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311(7010): 899-909.
5.
Ranson M, Davidson N, Nicolson M, et al.: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000; 92(13): 1074-1080.
6.
Anderson H, Hopwood P, Stephens RJ, et al.: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000; 83(4): 447-453.
7.
Roszkowski K, Pluzanska A, Krzakowski M, et al.: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapynaïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000; 27(3): 145-157.
8.
Cohen MH, Williams GA, Sridhara R, et al.: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003; 8(4): 303-306.
9.
Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21(14): 2787-2799.
Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001; 19(18 Suppl): 32S-40S.
12.
Chang GC, Yang TY, Wang NS, et al.: Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients. J. Formos Med Assoc. 2003; 102(6): 407-411.
13.
Ranson M, Hammond LA, Ferry D, et al.: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002; 20(9): 2240-2250.
Hammond LA: Pharmacokinetic evaluation of gefitinib when administered with chemotherapy. Clin Lung Cancer. 2003; 5Suppl 1: S18-S21.
16.
Rich JN, Reardon DA, Peery T, et al.: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004; 22(1): 133-142.
17.
Ciardiello F, Caputo R, Bianco R, et al: Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000; 6(5): 2053-2063.
18.
Woodburn JR, Barker AJ, Gibson KH, et al: ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Am Assoc Cancer Res. 1997; 38: 633-634.
19.
Woodburn JR, Wakeling A, Kelly H, et al: Preclinical studies with the oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘Iressa’) demonstrate significant anti-tumor activity. Signal Transduction Pathways and Regulation of Gene Expression as Therapeutic Targets meeting. 2000, January 26-29; Luxembourg.
20.
Kris M, Herbst R, Rischin D, et al: Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 2000; (suppl 1, abstr 231) 29: 72.
21.
Fukuoka M, Yano S, Giaccone G, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21(12): 2237-2246.
22.
Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290(16): 2149-2158.
23.
Cella D, Eton DT, Fairclough DL, et al.: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002; 55(3): 285-295.
24.
Herbst RS, LoRusso PM, Purdom M, et al: Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer. 2003; 4(6): 366-369.
25.
Van Doorn R, Kirtschig G, Scheffer E, et al.Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002; 147(3): 598-601.
26.
Okamoto I, Fujii K, Matsumoto M, et al.: Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer. 2003; 40(3): 339-342.
27.
Inoue A, Saijo Y, Maemondo M, et al.: Severe acute interstitial pneumonia and gefitinib. Lancet. 2003; 361(9352): 137-139.
28.
Miya T, Ono Y, Tanaka H, et al.: [Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report.]Nihon Kokyuki Gakkai Zasshi. 2003; 41(8): 565-568. Japanese.
29.
Ieki R, Saitoh E, Hashimoto E, et al.: [Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa)]Gan To Kagaku Ryoho. 2003; 30(7): 977-980. Japanese.
30.
Govindan R, Behnken D, Read W, et al.: Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. Ann Oncol. 2003; 14(8): 1330-1331.
31.
VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel: National Pharmacy Benefits Monograph Gefitinib (Iressa™) July 2003. Veteran’s Administration Web site. Available at http://www.vapbm.org/monograph/Gefitinib.pdf. Accessed March 25, 2004.
